2020 Lennox Gastaut Syndrome Market - Insights, Epidemiology & Market Forecast - ResearchAndMarkets.com

The "Lennox Gastaut Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Lennox Gastaut Syndrome (LGS) - Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the Lennox Gastaut Syndrome (LGS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Lennox Gastaut Syndrome (LGS) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted LGS symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lennox Gastaut Syndrome (LGS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Lennox Gastaut Syndrome (LGS) Disease Understanding and Treatment Algorithm

Lennox Gastaut Syndrome (LGS) Overview

Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that begins in childhood. It belongs to the group of the severe infantile epileptic syndrome (neonatal epileptic encephalopathy with suppression-burst, West syndrome, severe myoclonic epilepsy of infancy). Affected children experience several types of seizures, most commonly atonic, tonic and atypical absence seizures but generalized tonic-clonic and partial seizures can occur as well.

Three main criteria that define LGS are Multiple seizure types, mainly generalized, Abnormal electroencephalogram (EEG) with generalized slow spike-and-wave discharges (SSW) at < 2.5 Hz, Mental retardation or learning disabilities.

People with Lennox-Gastaut syndrome begin having frequent seizures in early childhood, usually between ages 3 and 5. LGS is also a physically dangerous epilepsy syndrome of childhood because of the frequent falls, injuries, and cognitive impairment that can severely limit the quality of life. Children affected might previously have infantile spasms or underlying brain disorder, but etiology can be idiopathic also.

In general, the causes of LGS is divided into two broader groups ; Identifiable causes, Cryptogenic (non-identifiable) causes. Identifiable causes include brain damage (e.g., head trauma), perinatal complications (e.g., birth asphyxia, intrauterine growth retardation, kernicterus), congenital central nervous system malformations (e.g., tuberous sclerosis), infections (e.g., meningitis, sepsis), or metabolic disorders.

Several key investigations are recommended for the difficulties mentioned above that are associated with diagnosed LGS.

Lennox Gastaut Syndrome (LGS) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Lennox Gastaut Syndrome (LGS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Lennox Gastaut Syndrome (LGS) market report gives a thorough understanding of LGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides LGS symptoms of treatment algorithms and treatment guidelines for LGS symptoms in the US, Europe, and Japan.

Lennox Gastaut Syndrome (LGS) Epidemiology

Lennox Gastaut Syndrome symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lennox Gastaut Syndrome (LGS) epidemiology segmented as the Total Prevalent cases of Lennox Gastaut Syndrome (LGS), Diagnosed Prevalent Cases of Lennox Gastaut Syndrome (LGS), Gender-Specific cases of Lennox Gastaut Syndrome (LGS), Seizure-specific cases of Lennox Gastaut Syndrome (LGS). The report includes the prevalent scenario of LGS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Scope of the Report

• The report covers the descriptive overview of Lennox Gastaut Syndrome (LGS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
• Comprehensive insight has been provided into the Lennox Gastaut Syndrome (LGS) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Lennox Gastaut Syndrome (LGS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Lennox Gastaut Syndrome (LGS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lennox Gastaut Syndrome (LGS) market

Report Highlights

• In the coming years, Lennox Gastaut Syndrome (LGS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Lennox Gastaut Syndrome (LGS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for LGS. Launch of emerging therapies will significantly impact the Lennox Gastaut Syndrome (LGS) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for LGS.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Key Topics Covered:

1. Key Insights

2. Lennox Gastaut Syndrome (LGS): Market Overview at a Glance

2.1. Market Share (%) Distribution of LGS in 2017

2.2. Market Share (%) Distribution of LGS in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Lennox Gastaut Syndrome (LGS)

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Types of Seizures associated with LGS

5.5. Etiology

5.6. Pathogenesis

5.7. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)

6.3. 7MM Total Diagnosed Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)

6.4. Country Wise-Epidemiology of Lennox Gastaut Syndrome (LGS)

6.5. United States

6.6. Germany

6.7. France

6.8. Italy

6.9. Spain

6.10. United Kingdom

6.11. Japan

7. Current Treatment Practices

7.1. Treatment Algorithm

7.2. Treatment Guidelines

7.2.1. NICE Guidelines

7.2.2. American Academy of Neurology (AAN)

8. Unmet needs

9. Marketed drugs

9.1. Lamictal: GlaxoSmithKline

9.2. Felbatol: Meda Pharmaceuticals

9.3. Klonopin: Roche

9.4. Onfi: Lundbeck

9.5. Epidiolex: Greenwich Biosciences

9.6. Banzel: Janssen Pharmaceuticals

9.7. Topamax: Janssen Pharmaceuticals

10. Emerging Therapies

10.1. Key cross competition

10.2. Phase-III Drugs

10.3. Fycompa (Perampanel): Eisai

10.4. Fintepla (ZX 008): Zogenix

10.5. Phase-II Drugs

10.6. TAK-935/ OV935: Takeda/Ovid

11. Lennox Gastaut Syndrome: 7 Major Market Analysis

11.1. Key Findings

11.2. Market Size of Lennox Gastaut Syndrome (LGS) in 7MM

12. Market Outlook by Country

13. The United States: Market Outlook

13.1. United States Market Size

13.2. EU-5 Countries: Market Outlook

13.3. Germany

13.4. France

13.5. Italy

13.6. Spain

13.7. United Kingdom

13.8. Japan: Market Outlook

14. Market Drivers

15. Market Barriers

16. Market access and Reimbursement

17. SWOT Analysis

18. Case studies

18.1. Epilepsy in Christianson syndrome: Case of Lennox-Gastaut syndrome

18.2. A Case of Lennox-Gastaut Syndrome in a 6-Year-Old Child with Moyamoya Disease

19. KOL Views

20. Appendix

21. Report Methodology

22. Capabilities

23. Disclaimer

24. About the Publisher

Companies Mentioned

• GlaxoSmithKline
• Meda Pharmaceuticals
• Roche
• Lundbeck
• Greenwich Biosciences
• Janssen Pharmaceuticals
• Eisai
• Zogenix
• Takeda/Ovid

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/oj3j2m

View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005425/en/